Company Announcement / Press release Archives - Page 8 of 19

Bulletin from the 2022 Annual General Meeting of Xspray Pharma AB (publ)

The following resolutions were passed at the annual general meeting (the “AGM”) of Xspray Pharma AB (publ) (“Xspray”) on 19 May 2022. Adoption of income statement and balance sheet for the financial year 2021 and discharge from liabilityThe AGM resolved to adopt the income statement and the consolidated income statement for the financial year 2021 […]

Xspray Pharma – Capital Markets Day Invitation

Xspray Pharma hereby invites investors, analysts, media representatives and other stakeholders to a Capital Markets Day, Tuesday May 24, 2022 at 10.00-12.00 CET, followed by lunch, at Hallvarsson & Halvarson, Sveavägen 20, Stockholm. The Capital Markets Day will be webcast between 10.00-12.00 CET. After the Capital Markets Day an on-demand replay will be available on […]

An eventful quarter sets the agenda for an intense 2022

First Quarter 2022 (January 1 – March 31), Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -18,934 thousand (-13,912) Earnings per share before dilution amounted to SEK -0.92 (-0.73) Cash flow from operating activities amounted to SEK -27,613 thousand (-11,971) Cash flow from investing activities amounted to SEK […]

The Nomination Committee’s proposal for the Board of Directors of Xspray Pharma AB

The Nomination Committee proposes Robert Molander as a new member of the Board of Directors at the Annual General Meeting. The Nomination Committee proposes that members of the Board of Directors Anders Ekblom (Chairman since 2021), Anders Bladh (member since 2021), Maris Hartmanis (member since 2015), Torbjörn Koivisto (member since 2017), Christine Lind (member since […]

Notice of annual general meeting of Xspray Pharma AB (publ)

The shareholders of Xspray Pharma AB (publ), Reg. No. 556649-3671, are summoned to the annual general meeting on Thursday 19 May 2022. Pursuant to temporary legislation, Xspray Pharma’s annual general meeting will be carried out through advance voting (postal voting) only. No meeting with the possibility to attend in person or to be represented by […]

Xspray Pharma publishes its annual report for 2021

“In 2021, we once again confirmed that Xspray Pharma’s unique technology platform can produce amorphous versions of protein kinase inhibitors. Having our processes in place means that we can shorten the development time for new products. I look forward to an intensive and productive 2022, during which Xspray Pharma’s organization will develop and mature, and […]

Update on recent developments regarding Dasynoc

Xspray Pharma AB (publ), (Nasdaq Stockholm: XSPRAY) today announced an update on recent developments regarding Xspray Pharma’s first product, Dasynoc, currently under review by the United States Food & Drug Administration (“FDA”). Bristol Myers Squibb (“BMS”) has filed a lawsuit in the United States District Court for the District of New Jersey against Xspray Pharma […]

Xspray Pharma publishes Q4 Year-End report 2021

”When looking back at Xspray Pharma’s fourth quarter 2021, I see it marked by hope for the future. After the end of the quarter, we reached a significant milestone when the US Food and Drug Administration (FDA) announced that it had agreed to review Xspray Pharma’s first product candidate: Dasynoc, an improved version of dasatinib. […]

Xspray Pharma appoints Global Head of Marketing and Sales

Xspray Pharma AB (publ), (Nasdaq Stockholm: XSPRAY) announced today that the company has hired Anna-Karin Ekberg as Global Head of Marketing and Sales. She will take office in mid-March 2022. “At the beginning of the year, Xspray Pharma reached a substantial milestone when the FDA accepted to review our first product. This means that we are getting […]

FDA allows review of application for market approval for Xspray Pharma’s Dasynoc™

Xspray Pharma (publ) (Nasdaq Stockholm: XSPRAY) announced today that the US Food and Drug Administration (FDA) has agreed to review the company’s application for market approval for Xspray Pharma’s product candidate, Dasynoc™ (dasatinib) in the US under the 505(b)(2) process. In November 2021, Xspray Pharma submitted an application for market approval in the US of […]